Stem definition | Drug id | CAS RN |
---|---|---|
halogenated compounds used as general inhalation anaesthetics | 1493 | 26675-46-7 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 18, 1979 | FDA | BAXTER HLTHCARE |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Mitochondrial DNA mutation | 153.36 | 61.26 | 24 | 2294 | 338 | 56289411 |
Propofol infusion syndrome | 139.31 | 61.26 | 25 | 2293 | 830 | 56288919 |
Intra-abdominal pressure increased | 126.49 | 61.26 | 19 | 2299 | 200 | 56289549 |
Pneumatosis | 120.65 | 61.26 | 20 | 2298 | 411 | 56289338 |
Status epilepticus | 115.00 | 61.26 | 37 | 2281 | 15104 | 56274645 |
Gene mutation | 108.18 | 61.26 | 22 | 2296 | 1427 | 56288322 |
Intestinal ischaemia | 105.38 | 61.26 | 29 | 2289 | 6926 | 56282823 |
Blood gases abnormal | 103.67 | 61.26 | 19 | 2299 | 710 | 56289039 |
Necrosis ischaemic | 101.46 | 61.26 | 19 | 2299 | 800 | 56288949 |
Apnoea | 95.11 | 61.26 | 27 | 2291 | 7215 | 56282534 |
Hyperthermia malignant | 90.35 | 61.26 | 17 | 2301 | 734 | 56289015 |
Delayed recovery from anaesthesia | 83.92 | 61.26 | 16 | 2302 | 742 | 56289007 |
Systemic inflammatory response syndrome | 79.90 | 61.26 | 22 | 2296 | 5256 | 56284493 |
Exposure during pregnancy | 76.66 | 61.26 | 55 | 2263 | 136287 | 56153462 |
Metabolic acidosis | 73.48 | 61.26 | 35 | 2283 | 40419 | 56249330 |
Post procedural complication | 70.89 | 61.26 | 26 | 2292 | 15640 | 56274109 |
Blood lactic acid increased | 68.00 | 61.26 | 20 | 2298 | 6044 | 56283705 |
Perforation | 61.31 | 61.26 | 13 | 2305 | 1033 | 56288716 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hyperthermia malignant | 234.83 | 54.51 | 48 | 2099 | 1936 | 31693261 |
Apnoea | 111.26 | 54.51 | 33 | 2114 | 6249 | 31688948 |
Post procedural complication | 102.01 | 54.51 | 35 | 2112 | 10571 | 31684626 |
Hypotension | 99.38 | 54.51 | 93 | 2054 | 204525 | 31490672 |
Intestinal ischaemia | 90.78 | 54.51 | 29 | 2118 | 7016 | 31688181 |
Necrosis ischaemic | 87.48 | 54.51 | 15 | 2132 | 225 | 31694972 |
Fear | 80.89 | 54.51 | 29 | 2118 | 9945 | 31685252 |
Anhedonia | 77.18 | 54.51 | 26 | 2121 | 7416 | 31687781 |
Injury | 74.42 | 54.51 | 33 | 2114 | 19676 | 31675521 |
Superinfection | 73.19 | 54.51 | 19 | 2128 | 2199 | 31692998 |
Renal injury | 68.04 | 54.51 | 26 | 2121 | 10639 | 31684558 |
Mucosal ulceration | 67.08 | 54.51 | 15 | 2132 | 923 | 31694274 |
Systemic inflammatory response syndrome | 65.53 | 54.51 | 22 | 2125 | 6203 | 31688994 |
Emotional distress | 60.56 | 54.51 | 26 | 2121 | 14330 | 31680867 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hyperthermia malignant | 305.31 | 44.99 | 62 | 4399 | 2599 | 70921384 |
Intestinal ischaemia | 207.77 | 44.99 | 61 | 4400 | 12003 | 70911980 |
Necrosis ischaemic | 180.01 | 44.99 | 34 | 4427 | 970 | 70923013 |
Hypotension | 152.49 | 44.99 | 155 | 4306 | 404226 | 70519757 |
Mitochondrial DNA mutation | 142.68 | 44.99 | 24 | 4437 | 345 | 70923638 |
Systemic inflammatory response syndrome | 140.77 | 44.99 | 44 | 4417 | 10668 | 70913315 |
Propofol infusion syndrome | 133.20 | 44.99 | 29 | 4432 | 1700 | 70922283 |
Intra-abdominal pressure increased | 116.13 | 44.99 | 19 | 4442 | 228 | 70923755 |
Fear | 112.17 | 44.99 | 44 | 4417 | 20767 | 70903216 |
Metabolic acidosis | 108.53 | 44.99 | 64 | 4397 | 74282 | 70849701 |
Renal injury | 108.25 | 44.99 | 40 | 4421 | 16054 | 70907929 |
Delayed recovery from anaesthesia | 108.20 | 44.99 | 24 | 4437 | 1533 | 70922450 |
Blood lactic acid increased | 106.55 | 44.99 | 36 | 4425 | 11137 | 70912846 |
Anhedonia | 105.54 | 44.99 | 38 | 4423 | 14175 | 70909808 |
Pneumatosis | 99.16 | 44.99 | 20 | 4441 | 806 | 70923177 |
Gene mutation | 93.88 | 44.99 | 23 | 4438 | 2268 | 70921715 |
Blood gases abnormal | 87.91 | 44.99 | 19 | 4442 | 1075 | 70922908 |
Emotional distress | 76.07 | 44.99 | 40 | 4421 | 37148 | 70886835 |
Status epilepticus | 75.94 | 44.99 | 35 | 4426 | 24491 | 70899492 |
Respiratory acidosis | 74.48 | 44.99 | 27 | 4434 | 10254 | 70913729 |
Injury | 74.37 | 44.99 | 48 | 4413 | 65197 | 70858786 |
Unevaluable event | 68.61 | 44.99 | 42 | 4419 | 52021 | 70871962 |
Anaesthetic complication | 66.58 | 44.99 | 18 | 4443 | 2618 | 70921365 |
Superinfection | 62.51 | 44.99 | 19 | 4442 | 4187 | 70919796 |
Mucosal ulceration | 58.43 | 44.99 | 15 | 4446 | 1786 | 70922197 |
Procedural hypotension | 57.12 | 44.99 | 15 | 4446 | 1951 | 70922032 |
Ultrasound ovary abnormal | 56.78 | 44.99 | 9 | 4452 | 87 | 70923896 |
Procedural complication | 55.42 | 44.99 | 20 | 4441 | 7494 | 70916489 |
Perforation | 53.35 | 44.99 | 13 | 4448 | 1252 | 70922731 |
Blood creatine phosphokinase increased | 52.96 | 44.99 | 38 | 4423 | 61225 | 70862758 |
Left ventricular hypertrophy | 52.94 | 44.99 | 21 | 4440 | 10181 | 70913802 |
Bradycardia | 52.57 | 44.99 | 51 | 4410 | 124564 | 70799419 |
Renal failure | 52.56 | 44.99 | 62 | 4399 | 189008 | 70734975 |
Multiple organ dysfunction syndrome | 50.70 | 44.99 | 47 | 4414 | 108468 | 70815515 |
Shock | 49.16 | 44.99 | 31 | 4430 | 40394 | 70883589 |
Exposure during pregnancy | 46.90 | 44.99 | 41 | 4420 | 87676 | 70836307 |
CSF oligoclonal band present | 46.69 | 44.99 | 9 | 4452 | 286 | 70923697 |
None
Source | Code | Description |
---|---|---|
ATC | N01AB06 | NERVOUS SYSTEM ANESTHETICS ANESTHETICS, GENERAL Halogenated hydrocarbons |
MeSH PA | D000777 | Anesthetics |
MeSH PA | D018685 | Anesthetics, Inhalation |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
CHEBI has role | CHEBI:38870 | inhalation anesthetics |
FDA EPC | N0000175681 | General Anesthetic |
FDA PE | N0000175975 | General Anesthesia |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
General anesthesia | indication | 50697003 | |
Hyperkalemia | contraindication | 14140009 | |
Low blood pressure | contraindication | 45007003 | |
Duchenne muscular dystrophy | contraindication | 76670001 | DOID:11723 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Malignant hyperthermia | contraindication | 405501007 |
Species | Use | Relation |
---|---|---|
Dogs | Induction and maintenance of general anesthesia | Indication |
Horses | Induction and maintenance of general anesthesia | Indication |
Product | Applicant | Ingredients |
---|---|---|
IsoFlo | Zoetis Inc. | 1 |
Isoflurane, USP | Dechra Veterinary Products LLC | 1 |
ATTANE | Piramal Critical Care Inc. | 1 |
Isoflurane, USP | Piramal Enterprises Ltd. | 1 |
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
GABA-A receptor; anion channel | Ion channel | POSITIVE ALLOSTERIC MODULATOR | CHEMBL | CHEMBL | |||||
Potassium channel subfamily K member 2 | Ion channel | OPENER | CHEMBL | CHEMBL | |||||
Potassium channel subfamily K member 3 | Ion channel | OPENER | CHEMBL | CHEMBL | |||||
Potassium channel subfamily K member 9 | Ion channel | OPENER | CHEMBL | CHEMBL | |||||
Potassium channel subfamily K member 10 | Ion channel | OPENER | CHEMBL | CHEMBL | |||||
Potassium channel subfamily K member 18 | Ion channel | OPENER | CHEMBL | CHEMBL | |||||
Glycine receptor (alpha-1/beta) | Ion channel | POSITIVE MODULATOR | CHEMBL | CHEMBL | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 5.11 | PDSP |
ID | Source |
---|---|
4019107 | VUID |
N0000147364 | NUI |
D00545 | KEGG_DRUG |
4019107 | VANDF |
C0022180 | UMLSCUI |
CHEBI:6015 | CHEBI |
ICF | PDB_CHEM_ID |
CHEMBL1256 | ChEMBL_ID |
DB00753 | DRUGBANK_ID |
D007530 | MESH_DESCRIPTOR_UI |
3763 | PUBCHEM_CID |
3286 | INN_ID |
2505 | IUPHAR_LIGAND_ID |
CYS9AKD70P | UNII |
6026 | RXNORM |
284 | MMSL |
4326 | MMSL |
4926 | MMSL |
d00267 | MMSL |
001391 | NDDF |
387368002 | SNOMEDCT_US |
66492008 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
FORANE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10019-360 | INHALANT | 1 mL | RESPIRATORY (INHALATION) | NDA | 23 sections |
FORANE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10019-360 | INHALANT | 1 mL | RESPIRATORY (INHALATION) | NDA | 23 sections |
Isoflurane | HUMAN PRESCRIPTION DRUG LABEL | 1 | 12164-012 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 22 sections |
Terrell | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-011 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 13 sections |
Terrell | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-011 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 13 sections |
Terrell | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-011 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 13 sections |
Isoflurane | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-017 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 21 sections |
Isoflurane | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-017 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 21 sections |
Terrell | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-019 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 21 sections |
Terrell | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-019 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 21 sections |
Isoflurane | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-020 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 13 sections |
Isoflurane | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-020 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 13 sections |
Isoflurane | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-020 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 13 sections |